Alembic Pharmaceuticals receives tentative US FDA approval for generic Bosutinib leukemia tablets.
Alembic Pharmaceuticals, an Indian company, has received tentative approval from the US FDA for its generic Bosutinib tablets, used to treat a type of leukemia called Philadelphia chromosome-positive chronic myelogenous leukemia. The estimated market size for these tablets is $275M. This approval increases Alembic's cumulative total USFDA approvals to 206, including 179 final approvals and 27 tentative approvals.
July 01, 2024
3 Articles